Tomohiro Hanazawa1,2, Kei Asayama1,3, Yutaka Imai1, Takayoshi Ohkubo3. 1. Department of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan. 2. Japan Development and Medical Affairs, GlaxoSmithKline KK, Tokyo, Japan. 3. Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan.
Authors: Christina Pamporaki; Michael Bursztyn; Manja Reimann; Tjalf Ziemssen; Stefan R Bornstein; Fred C G J Sweep; Henri Timmers; Jacques W M Lenders; Graeme Eisenhofer Journal: Eur J Endocrinol Date: 2014-02-04 Impact factor: 6.664